Medeon Biodesign, Inc. (TPEX:6499)
Taiwan · Delayed Price · Currency is TWD 72.80
-0.20 (-0.27%)
Sep 8, 2026, 12:38 PM CST
Medeon Biodesign Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 7,077 | 8,717 | 3,654 | 4,294 | 5,092 | 6,592 | |
Market Cap Growth | -21.55% | 138.60% | -14.91% | -15.67% | -22.76% | 80.99% |
Enterprise Value | 6,308 | 7,982 | 2,482 | 2,208 | 3,643 | 4,155 |
Last Close Price | 73.00 | 94.50 | 39.26 | 46.19 | 54.26 | 69.38 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | - | 3.17 |
Forward PE | - | 16.78 | 16.78 | 16.78 | 16.78 | 49.52 |
PS Ratio | 16.53 | 20.78 | 12.48 | 21.88 | 17.07 | 95.60 |
PB Ratio | 5.58 | 5.67 | 2.38 | 1.81 | 1.39 | 1.57 |
P/TBV Ratio | 6.54 | 6.59 | 2.69 | 2.00 | 1.49 | 1.63 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 14.74 | 19.03 | 8.48 | 11.25 | 12.21 | 60.25 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.12 | 0.07 | 0.11 | 0.08 | 0.05 | 0.01 |
Net Debt / Equity Ratio | -0.64 | -0.72 | -0.68 | -0.82 | -0.37 | -0.55 |
Net Debt / EBITDA Ratio | 1.42 | 1.66 | 1.24 | 2.45 | 2.93 | 5.01 |
Net Debt / FCF Ratio | 1.55 | 1.71 | 1.15 | 2.41 | 2.24 | 7.69 |
Asset Turnover | 0.29 | 0.23 | 0.13 | 0.06 | 0.07 | 0.02 |
Inventory Turnover | 13.24 | 12.24 | 9.33 | 17.47 | - | - |
Quick Ratio | 6.17 | 7.87 | 5.81 | 9.89 | 8.09 | 14.76 |
Current Ratio | 6.57 | 8.21 | 6.11 | 10.05 | 8.25 | 14.91 |
Return on Equity (ROE) | -51.16% | -46.82% | -44.56% | -42.09% | -12.66% | -17.16% |
Return on Assets (ROA) | -26.09% | -24.69% | -23.94% | -15.46% | -7.26% | -8.07% |
Return on Capital Employed (ROCE) | -44.70% | -44.60% | -53.30% | -33.20% | -12.70% | -11.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -7.89% | -7.66% | -22.05% | -28.06% | -8.52% | 31.53% |
FCF Yield | -7.36% | -7.41% | -24.82% | -18.87% | -11.82% | -4.58% |
Dividend Yield | - | - | - | - | 0.88% | 1.14% |
Buyback Yield / Dilution | -2.70% | -0.21% | -0.11% | -0.02% | 0.07% | -0.48% |
Total Shareholder Return | -2.70% | -0.21% | -0.11% | -0.02% | 0.95% | 0.66% |